Vol.5 Neurodegenerative Brain Disorders

Vol.5 Neurodegenerative Brain Disorders

Editors:Tomás Palomo, Richard J. Beninger, Trevor Archer

December 2000

Publisher: Editorial CYM, General Oráa, 47, 28006 MADRID

ISBN: 84-921848-2-5

Pages: 813


Neurotoxicology, Degeneration and Protection in Brain Disease States

Mojácar (Almería)

October 15 - 19 1999

The content of this congress, together with other contributions on the topic, are collected in vol. 5 of the series "Strategies for studying brain disorders".



  • Tamas Bartfai, Switzerland.
    Cytokines in brain during fever and traumatic brain injury.
  • Friedbert Weiss, USA.
    Neurotoxicological consequences of addiction.
  • Eduardo Molina-Holgado, Spain.
    Cytokine effects in oligodendrocytes: Implications for the pathogenesis of multiple sclerosis.
  • Gaetano Di Chiara, Italy.
    Moving the border between neuroadaptation and neurotoxicity: the case of behavioural sensitization by psychostimulants, dopamine agonists and neuroleptics.
  • John Harvey, USA.
    Effects of prenatal exposure to cocaine on the developing brain: anatomical, chemical, physiological and behavioral consecuences.
  • Pierre Sokoloff, France.
    A partial dopamine D3 receptor agonist as a new medication for drug addiction.
  • Per Eriksson, Sweden.
    Toxicological destruction of cholinergic systems: Implications for psychiatric and neurological conditions.
  • Thomas H. Rupniak, UK.
    Oxidative neuropathology and putative chemical entities for Alzheimer's disease.
  • João Quevedo, Brazil.
    What may go wrong when memory fails: the main biochemical events underlying memory consolidation and retrieval in rats.
  • Eduardo Rodríguez-Farré, Spain.
    Old and new problems in human neurotoxicology.
  • Vicente Molina, Spain.
    Neuroimaging studies on degeneration in schizophrenia.
  • John W. Olney, USA.
    Neurotoxicological processes in schizophrenia.
  • José Borrell, Spain.
    Sensory-motor gating in immune challenged rats: Implications for the etiopathogenesis of schizophrenia.


  • Ryan J. Uitti, USA.
    Neuroprotection conferred by sex in parkinsonism.
  • Donald B. Calne, Canada.
    Hereditary versus environmental causes for neurodegeneration.
  • Roger L. Albin, USA.
    Huntington disease: A model excitotoxic chronic neurodegeneration.
  • Antonio Lobo, Spain.
    Epidemiology of Alzheimer's disease: Implications for Neurodegeneration.
  • Isidro Ferrer, Spain.
    Neurotrophin signaling in Alzheimer's disease: Implications in therapeutic strategies.
  • Richard Beninger, Canada.
    Cognitive effects of neurotoxic lesions of the nucleus basalis magnocellularis in rats: differential roles for corticopetal versus amygdalopetal projections.
  • Bita Moghaddam, USA.
    Metabotropic glutamate receptors and NMDA model of psychosis.
  • Jose Mª Delgado, Spain.
    Neuronal adaptability to target removal in motor and premotor systems.
  • Michel le Moal, France.
    Perinatal life events: long term consequences.
  • Fernando Rodríguez de Fonseca, Spain.
    Role for the endogenous cannabinoid system as a modulator of dopamine transmission in the striatum: Implications for Parkinson's disease and schizophrenia.
  • Lewis S. Seiden, USA.
    3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in core body temperature in the rat are affected by small changes in ambient temperature.
  • George Ricaurte, USA.
    Amphetamine derivatives and neurodegeneration.
  • Barry E. Kosofsky, USA.
    Dose-related alterations in juvenile and adult behavior, neocortical cytoarchitecture and dopaminergic signal transduction following prenatal cocaine exposure in mice.


  • M.Flint Beal, USA.
    Available and potential neuroprotective agents in free radical onslaught.
  • Wojciech Danysz, Germany.
    NMDA receptor antagonists as potential treatment for neurodegenerative dementia. Lesson from Memantine story.
  • Khem Jhamandas, Canada.
    Excitotoxicity of quinolinic acid: Modulation by endogenous factors.
  • Manuel Vidal-Sanz, Spain.
    Death and neuroprotection of retinal ganglion cells after transient ischemia.
  • Chuang C. Chiueh, USA.
    Neuroprotective strategies in Parkinson's disease: Protection against progressive nigral damage induced by free radicals and iron complexes.
  • Manfred Gerlach, Germany.
    Protective methods against neurotoxins.
  • Trevor Archer, Sweden.
    Restoration and putative protection of MPTP-induced functional deficits.
  • Agneta Nordberg, Sweden.
    Neuroprotection in Alzheimer's disease. New strategies for treatment.
  • Justo García de Yébenes, Spain.
    Neurotroprophic factors in neurodegenerative disorders.
  • Francisco Grandas, Spain.
    The putative neuroprotective role of dopamine agonists in Parkinson's disease.
  • Werner J. Schmidt, Germany.
    The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.
  • Richard M. Kostrzewa, USA.
    Neurotoxicity and neurodegeneration among the shifting sand dunes of protection.

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+